title: [Alpha-1-antitrypsin in early infections after hip prosthesis surgery].
abstract: OBJECTIVE
  The aim of this work was to determine whether erythrocyte sedimentation rate (ESR), C-reactive protein (CRP) and alpha-1-antitrypsin (A1AT) levels are correlated significantly with early postoperative infectious complications after hip prosthetic surgery.
  
  
  METHODS
  This prospective study was conducted on 100 total hip replacements performed between 1994 and 1995. ESR, CRP and A1AT were obtained before surgery then at 1, 2 and 6 weeks after surgery.
  
  
  RESULTS
  Seven bacteriologically proven cases of infection were reported. Infection was considered to be superficial if it did not extend deeper than the muscles fascia. There was a strong statistical correlation between A1AT level and infection for all postoperative times (p<0.0001). A1AT was highly sensitive (87.5 p. 100) and specific (85.8 p. 100) for infection compared with ESR (sensibility 70 p. 100 and specificity 65.9 p. 100) and CRP (sensitivity 63.6 p. 100 and specificity 80.1 p. 100).
  
  
  CONCLUSIONS
  In our hands, A1AT can be a most useful diagnostic tool for infection after prosthesis hip surgery. Although not totally specific, it is highly sensitive for infection compared with other tools such as ESR and CRP more frequently used. These findings suggest an avenue of research on the role of A1AT in infectious complications after prosthetic joint surgery.
authors.affiliation: Service de Chirurgie Orthopédique et de Traumatologie, Complejo Hospitalario de Ciudad Real, Ciudad Real, Espagne.
authors.forename: L A
authors.initials: LA
authors.lastname: Gómez Navalón
authors.forename: J A
authors.initials: JA
authors.lastname: Salido Valle
authors.forename: A
authors.initials: A
authors.lastname: López Alonso
mesh_terms: D000151:Acinetobacter Infections / Q000097:blood / Q000175:diagnosis* / Q000517:prevention & control; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000900:Anti-Bacterial Agents / Q000008:administration & dosage / Q000627:therapeutic use; D019072:Antibiotic Prophylaxis; D001799:Blood Sedimentation; D002097:C-Reactive Protein / Q000032:analysis; D002435:Cefamandole / Q000008:administration & dosage / Q000627:therapeutic use; D002511:Cephalosporins / Q000008:administration & dosage / Q000627:therapeutic use; D004796:Clinical Enzyme Tests; D003627:Data Interpretation, Statistical; D005260:Female; D006622:Hip Prosthesis / Q000009:adverse effects*; D006801:Humans; D008297:Male; D008875:Middle Aged; D009391:Nephelometry and Turbidimetry; D011182:Postoperative Care; D011446:Prospective Studies; D016459:Prosthesis-Related Infections / Q000097:blood / Q000175:diagnosis* / Q000517:prevention & control; D012680:Sensitivity and Specificity; D013203:Staphylococcal Infections / Q000097:blood / Q000175:diagnosis* / Q000517:prevention & control; D013212:Staphylococcus epidermidis; D013997:Time Factors; D014031:Tobramycin / Q000008:administration & dosage / Q000627:therapeutic use; D014640:Vancomycin / Q000008:administration & dosage / Q000627:therapeutic use; D000515:alpha 1-Antitrypsin / Q000032:analysis*
chemical_list: D000900:Anti-Bacterial Agents; D002511:Cephalosporins; D000515:alpha 1-Antitrypsin; D002435:Cefamandole; D014640:Vancomycin; D002097:C-Reactive Protein; D014031:Tobramycin